This website uses cookies, which are necessary for the technical operation of the website and are always set. Other cookies, which increase the comfort when using this website, are used for direct advertising or to facilitate interaction with other websites and social networks, are only set with your consent.
Configuration
Technically required
These cookies are necessary for the basic functions of the shop.
"Allow all cookies" cookie
"Decline all cookies" cookie
CSRF token
Cookie preferences
Currency change
Customer-specific caching
FACT-Finder tracking
Individual prices
Selected shop
Session
Comfort functions
These cookies are used to make the shopping experience even more appealing, for example for the recognition of the visitor.
Note
Show the facebook fanpage in the right blod sidebar
Statistics & Tracking
Affiliate program
Conversion and usertracking via Google Tag Manager
Solubility: Soluble in DMSO at 2 mg/mL with warming, very poorly soluble in ethanol, very poorly soluble in water, maximum solubility in plain water is estimated to be about 5-20 µM, buffers, serum, or other additives may increase or decrease the aqueous solubility. Neratinib, also known as HKI-272, is considered to be a second-generation inhibitor of the ErbB family of receptor kinases. Sequist, L.V., et al. 'Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.' Oncologist 12: 325-330 (2007). Neratinib is an irreversible inhibitor of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER-2) tyrosine kinases by targeting a cysteine residue in the ATP-binding site of the receptor. Rabindran, S.K., et al. 'Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase.' Cancer Res. 64: 3958-3965 (2004). Neratinib inhibits the proliferation of HER-2 overexpressing human breast cancer cell lines and EGFR-dependent cells in vitro. In vivo, neratinib is active against HER-2- and EGFR-dependent tumor xenograft models. Rabindran, S.K., et al. 'Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase.' Cancer Res. 64: 3958-3965 (2004). Acquired resistance of non-small cell lung cancers to gefitinib because of a T790M mutation in the EGFR kinase domain is circumvented by neratinib. Kwak, E.L., et al. 'Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.' Proc. Natl. Acad. Sci. USA 102: 7665-7670 (2005). Neratinib is active against HER-2-positive breast cancer in patients. Wong, K.K., et al. 'HKI-272, an irreversible pan erbB receptor tyrosine kinase inhibitor: Preliminary phase 1 results in patients with solid tumors.' J. Clin. Oncol. 24: 3018 (2006).
This website uses cookies, which are necessary for the technical operation of the website and are always set. Other cookies, which increase the usability of this website, serve for direct advertising or simplify interaction with other websites and social networks, will only be used with your consent.
More information